Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

Max Yano, Jennie Rachel Lance, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4302.

https://doi.org/10.1182/blood-2019-127620

Published: 2019

Journal Articles

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Jennie Rachel Lance, Max Yano, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4303.

https://doi.org/10.1182/blood-2019-131034

Published: 2019

Journal Articles

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Meixiao Long, MD, Erich Williams, Clara Berard, Carolyn Cheney, BS, Eileen Hu, BS, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1049.

https://doi.org/10.1182/blood-2019-125417

Published: 2019

Journal Articles

Protein Phosphatase 2A Activation Dependent Down Regulation of PGC1-Alpha and FOXO1 Phosphorylation with OSU-2S in Human Lymphoma Cells

Sohaila Mohamed Khalil, Swagata Goswami, MSc, Xiaokui Mo, PhD MAS, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3977.

https://doi.org/10.1182/blood-2019-129224

Published: 2019

Journal Articles

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Swagata Goswami, MSc, Chi-Ling Chiang, PhD, Kevan Zapolnik, BS, Zhiliang Xie, James L. Lee, PhD, Sivasubramanian Baskar, Christoph Rader, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Bhavana Bhatnagar, DO, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3798.

https://doi.org/10.1182/blood-2019-128828

Published: 2019

Journal Articles

LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia

Eileen Hu, BS, Hatice Gulcin Ozer, PhD, Arletta Lozanski, Tzyy-Jye Doong, Chi-Ling Chiang, PhD, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, James S. Blachly, MD, Gerard Lozanski, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 3377.

https://doi.org/10.1182/blood-2019-126070

Published: 2019

Journal Articles

CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy

Karilyn Larkin, MD, Erin Guth, MS, Bonnie K. Harrington, DVM, Nicole Grieselhuber, MD PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 4056.

https://doi.org/10.1182/blood-2018-99-117262

Published: 2018

Journal Articles

The ETS1 Transcription Factor Is Implicated in Human and Murine Intermediate NK Cell Development Stages

Eileen Hu, BS, Jessica Waibl-Polania, BS, Frank Frissora, MS, Larry State Beaver, Kevan Zapolnik, BS, Bethany L Mundy-Bosse, PhD, Anjali Mishra, PhD, Aharon G. Freud, MD PhD, Jianhua Yu, PhD, John C. Byrd, MD, Christopher C. Oakes, Michael Ostrowski, PhD, Natarajan Muthusamy, DVM, PhD

Blood (2018) 132 (Supplement 1): 2567.

https://doi.org/10.1182/blood-2018-99-115261

Published: 2018

Journal Articles

Par-4 Overexpression Impedes Leukemogenesis in the Eµ-TCL1 Leukemia Model

Joseph Thomas Greene, BS, Rahul Ramaswamy, Mary K McKenna, BS, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Ronni Wasmuth, BS, Minh Tran, BS, Xiaokui Mo, PhD MAS, Carlo M. Croce, MD, Vivek Rangnekar, PhD, John C. Byrd, MD, Subbarao Bondada, PhD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1223.

https://doi.org/10.1182/blood.V130.Suppl_1.1223.1223

Published: 2017

Journal Articles

Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eileen Hu, BS, Priscilla Do, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Haiyong Peng, PhD, Lorenz Waldmeier, PhD, Roger Beerli, PhD, Christoph Rader, PhD, Ulf Grawunder, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 3017.

https://doi.org/10.1182/blood.V130.Suppl_1.3017.3017

Published: 2017

Journal Articles

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Farrukh T. Awan, MD MS, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD, Leslie Andritsos, MD, Natarajan Muthusamy, DVM,PhD, Barbara Andersen, PhD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 1748.

https://doi.org/10.1182/blood.V130.Suppl_1.1748.1748

Published: 2017

Journal Articles

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

Chi-Ling Chiang, MS, Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Zhiliang Xie, Xiaomeng Huang, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, PhD, Mitch A. Phelps, PhD, Guido Marcucci, MD, John C. Byrd, MD, James L. Lee, PhD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 4981.

https://doi.org/10.1182/blood.V130.Suppl_1.4981.4981

Published: 2017

Journal Articles

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Xiaokui Mo, PhD MAS, Pearlly S. Yan, PhD, Michael B Broe, PhD, Ralf Bundschuh, PhD, Larry State Beaver, Kevan Zapolnik, BS, Zhiliang Xie, Donna Bucci, David M. Lucas, PhD, Allison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Ching-Shih Chen, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MDMBBS, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1247.

https://doi.org/10.1182/blood.V130.Suppl_1.1247.1247

Published: 2017

Journal Articles

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM PhD, Chi-Ling Chiang, MS, Frank W Frissora, M.S., Xiaokui Mo, PhD MAS, Zhiliang Xie, Donna Bucci, Amber Gordon, MLS, David M. Lucas, PhD, William Blum, MD, Alison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ching-Shih Chen, PhD, Robert J Lee, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2748.

https://doi.org/10.1182/blood.V128.22.2748.2748

Published: 2016

Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Deborah M Stephens, DO, Kyle A. Beckwith, PhD, Priscilla Do, BS, Carolyn Cheney, BS, Xiaokui Mo, PhD MAS, Karilyn Larkin, MD, Jeffrey Jones, MD MPH, Farrukh T. Awan, Laura Grosmaire, PhD, Randy Jones, PhD, Julie DiPaolo, PhD, Stacey Tannheimer, Karl-Heinz Heider, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2767.

https://doi.org/10.1182/blood.V128.22.2767.2767

Published: 2016

Journal Articles

PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

Porsha L. Smith, PhD, Fengting Yan, MD PhD, John T. Patton, PhD, Lapo Alinari, MD PhD, Vrajesh Karkhanis, PhD, Leona Ayers, MD, Natarajan Muthusamy, DVM, PhD, Anjali Mishra, PhD, Elshafa Ahmed, DVM, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2016) 128 (22): 2936.

https://doi.org/10.1182/blood.V128.22.2936.2936

Published: 2016

Journal Articles

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Rajeswaran Mani, DVM PhD, Swagata Goswami, MS, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, PhD MAS, Amber Gordon, MLS, Donna Bucci, David Lucas, PhD, Christopher L. Brooks, PhD, Alison R. Walker, MD MPH, William Blum, MD, John C. Byrd, MD, Gerard Lozanski, MD, Sumithra Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 580.

https://doi.org/10.1182/blood.V128.22.580.580

Published: 2016

Journal Articles

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Priscilla Do, BS, Kyle A. Beckwith, PhD, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, PhD MAS, Jeffrey Jones, MD MPH, Erin K. Hertlein, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3221.

https://doi.org/10.1182/blood.V128.22.3221.3221

Published: 2016

Journal Articles

BRAF V600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia

Yo-Ting Tsai, MS, Aparna Lakshmanan, PhD, Amy M. Lehman, MAS, Ellen J. Sass, Minh Tran, Fabienne McClanahan, MD PhD, Meixiao Long, MD PhD, Bonnie K. Harrington, DVM, Krista La Perle, DVM, PhD, Vincenzo Coppola, MD, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD, Michael R. Grever, MD, David M. Lucas, PhD

Blood (2016) 128 (22): 1206.

https://doi.org/10.1182/blood.V128.22.1206.1206

Published: 2016

Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3238.

https://doi.org/10.1182/blood.V128.22.3238.3238

Published: 2016

NARROW

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Protein Phosphatase 2A Activation Dependent Down Regulation of PGC1-Alpha and FOXO1 Phosphorylation with OSU-2S in Human Lymphoma Cells

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia

CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy

The ETS1 Transcription Factor Is Implicated in Human and Murine Intermediate NK Cell Development Stages

Par-4 Overexpression Impedes Leukemogenesis in the Eµ-TCL1 Leukemia Model

Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

BRAF V600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only